Fig. 5

Increased CSF-decorin in three different mouse models of Aβ pathology. a, b Immunostaining and quantification of decorin in the ChP. Scale bars, 100 µm. (n = 4). c Double immunostaining of DCN and PV or d SRIF in mouse hippocampus. e Quantification of decorin-positive cell-type distribution. Scale bars, 500 µm. (n = 3). f, g Immunostaining and quantification of decorin in the hippocampus. Scale bars, 500 µm. (n = 4). h Mouse CSF-decorin levels in three months old (n = 5), i 13 months old (n = 4–5), j 18 months old (n = 3–5) mice were measured by ELISA and quantified. k CSF-decorin levels in App^NL-F/NL-F mice of different ages were measured and quantified. (n = 3–5). l Decorin levels in Aβ42 treated mouse primary neurons and (m) were quantified (n = 4). n Quantification of decorin levels in conditioned media. (n = 8). Data in (b, g–k) were analyzed by one-way ANOVA followed by Dunnett’s multiple comparisons test. Data in (m, n) were analyzed by student’s t-test. Data in (e) were analyzed by two-way ANOVA followed by Tukey’s post hoc test. Data are represented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. DCN decorin, PV parvalbumin, SRIF somatotropin release-inhibiting factor, PN pyramidal neurons, ns not significant